C12N 2760/16262
By genetic engineering
Official title: by genetic engineering
C12N2760/16262 (By genetic engineering) appears on 30 US grants and 36 published applications in this corpus.
Search patents in C12N- Granted patents
- 30
- Published applications
- 36
- Assignees
- 14
- Inventors
- 33
- Latest grant
- 19 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 2 | 0 |
| 2004 | 0 | 2 |
| 2005 | 1 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 2 | 4 |
| 2010 | 0 | 2 |
| 2011 | 2 | 1 |
| 2012 | 1 | 4 |
| 2013 | 3 | 0 |
| 2014 | 3 | 4 |
| 2015 | 0 | 0 |
| 2016 | 4 | 4 |
| 2017 | 0 | 0 |
| 2018 | 2 | 2 |
| 2019 | 0 | 1 |
| 2020 | 1 | 4 |
| 2021 | 2 | 0 |
| 2022 | 2 | 3 |
| 2023 | 0 | 1 |
| 2024 | 3 | 1 |
| 2025 | 1 | 1 |
By publication year.
Recent patents
- Influenza b virus mutants and uses therefor19 Aug 2025US 12,390,519 B2FluGen, Inc.
- Live attenuated influenza B virus compositions methods of making and using thereof3 Dec 2024US 12,156,910 B2Versitech Limited
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof16 Jul 2024US 12,037,364 B2Sanofi Pasteur Limited
- Influenza virus mutants and uses therefor14 May 2024US 11,980,661 B2FluGen, Inc.
- Influenza B virus mutants and uses therefor20 Dec 2022US 11,529,409 B2FluGen, Inc.
- Influenza virus mutants and uses therefor20 Mar 2025US 2025/0090649 A1FluGen, Inc.
- Influenza b virus mutants and uses therefor21 Mar 2024US 2024/0091337 A1FluGen, Inc.
- Compositions immunogenic against sars coronavirus 2, methods of making, and using thereof23 Mar 2023US 2023/0089695 A1Versitech Limited
- Influenza virus mutants and uses therefor29 Dec 2022US 2022/0409719 A1FluGen, Inc.
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof4 Aug 2022US 2022/0242918 A1Sanofi Pasteur Limited
Most cited
By later US patents
- Multi plasmid system for the production of influenza virus40US 8,012,736 B2MedImmune, LLC · 2011
- Methods and interferon deficient substrates for the propagation of viruses37US 6,852,522 B1Mount Sinai School of Medicine of New York University · 2005
- Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals35US 6,669,943 B1Mount Sinai School of Medicine of New York University · 2003
- Methods and interferon deficient substrates for the propagation of viruses34US 6,573,079 B1Mount Sinai School of Medicine of New York University · 2003
- Methods and interferon deficient substrates for the propagation of viruses33US 7,494,808 B2Mount Sinai School of Medicine of New York University · 2009